Skip to main content

Cellectar shares inventor, investor and CEO perspectives at WARF Gilson Series

June 18, 2009

The perspectives of the inventor, investor and CEO of Madison’s rising startup radiopharmaceutical company Cellectar Inc. will be the focus of the Wisconsin Alumni Research Foundation‘s Gilson Discovery Series event, to be held at 5 p.m. on Wednesday, June 24, at the Fluno Center, 601 University Ave.

Cellectar, which is developing therapies to detect, treat and monitor a wide variety of human cancers, recently received FDA clearance to enter clinical trials with its lead drug candidate.

Jamey Weichert, inventor and primary founder of Cellectar, and a professor at the University of Wisconsin–Madison School of Medicine and Public Health; John Neis, investor and managing director of Venture Investors LLC; and Bill Clarke, chief executive officer of Cellectar, will share how this startup has aligned its management and research to meet regulatory demands and achieve marketplace success to improve human health. They will discuss their roles and experiences in combining innovation and teamwork, as well as technologies from multiple universities.

The event is free and open to the public as part of the Gilson Discovery Series hosted by the Wisconsin Alumni Research Foundation (WARF). The panel discussion is followed by a networking reception at 6 p.m. Complimentary parking is available by registering online or by calling 608-890-1621.